Investment firm Flagship Pioneering on Tuesday launched its first U.K. biotech. Quotient Therapeutics, a company studying genetic variation on the cellular level, joins 41 other companies in the firm’s ecosystem.

After a two-year incubation period in the investment firm, Quotient is stepping out on its own with a $50 million commitment from Flagship “to advance development of the company’s platform,” and “pursue a pipeline of medicines across a wide range of therapeutic areas and modalities,” according to the companies’ announcement.

Quotient will be focused on studying somatic genomics with an eye to finding new targets for gene therapies and treatments.

“All cells accumulate random genetic changes in their DNA, resulting in trillions of unique genomes in the body,” Quotient CEO Geoffrey von Maltzahn said in a statement. “Some genetic changes make a cell resistant or vulnerable to disease, while others can cause disease. We started Quotient to study the natural genetics library inside every tissue, discover gene variants that are beneficial, neutral, or disease-causing, and to harness that knowledge to develop the medicines of tomorrow.”

Tracking variation on that level requires extreme granularity. Quotient’s model is reliant on its proprietary single-molecule genome sequencing technology, created in partnership with Flagship, U.K.-based Wellcome Sanger Institute and the University of Texas Southwestern. The platform studies cells using four steps: cell phenotyping from tissue samples, then isolation, single cell genotyping, and then computation.

“As a result, naturally selected genes, proteins, and pathways are identified as prospective targets for the development of transformative therapies intended to cure, prevent, or reverse disease,” the companies said in the press release.

Quotient President Jacob Rubens added that “we’ve created the world’s largest somatic genomes dataset, demonstrated the applicability of our platform to multiple therapeutic areas, and translated our genetic discoveries into drug discoveries.”

This also marks a first for Flagship Pioneering, as Quotient will be based in both Cambridge, Mass. and Cambridge, U.K. It’s also an unusual step for Flagship, which has generally kept its startups near its home base of Boston, though the co-location across the pond does give the company proximity to its partners at the Wellcome Sanger Institute.

Flagship has been expanding its presence recently, notably into the U.K. and Asia, particularly with the launch of a regional hub in Singapore.

The investment firm launched in 2000 and in the 23 years since has “originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value,” according to Flagship, while deploying over $3.4 billion in capital toward the founding and growth of “its pioneering companies” along with more than $26 billion of follow-on investments from other institutions.

Source: https://www.biospace.com/article/flagship-pioneering-launches-first-uk-biotech-with-50m-investment/
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

How to make mRNA therapeutics safe from the start

The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...

read more